[Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
Shuichi
S
Miyawaki
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D060830:Consolidation Chemotherapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D055808:Drug Discovery / Q000639:trends; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D060828:Induction Chemotherapy; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000628:therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000628:therapy*; D060046:Maintenance Chemotherapy; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D058990:Molecular Targeted Therapy; D009154:Mutation; D012008:Recurrence; D014212:Tretinoin / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014212:Tretinoin; D014750:Vincristine; D005047:Etoposide; D015122:Mercaptopurine; D008727:Methotrexate; D015255:Idarubicin; D003630:Daunorubicin